Neurocrine Biosciences, Inc. Free Cash Flow 2009–2025
Neurocrine Biosciences, Inc. reported $748.70M of free cash flow for fiscal 2025. That was 34.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +244.1%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $748.70M | +34.4% |
| FY 2024 | $557.20M | +54.1% |
| FY 2023 | $361.60M | +12.0% |
| FY 2022 | $322.90M | +38.5% |
| FY 2021 | $233.10M | +7.1% |
| FY 2020 | $217.60M | +64.5% |
| FY 2019 | $132.30M | +72.7% |
| FY 2018 | $76.60M | +175.6% |
| FY 2017 | $-101.27M | +8.2% |
| FY 2016 | $-110.29M | -176.2% |
| FY 2015 | $-39.93M | +18.1% |
| FY 2014 | $-48.75M | -61.7% |
| FY 2013 | $-30.15M | +16.9% |
| FY 2012 | $-36.27M | -2404.5% |
| FY 2011 | $-1.45M | -102.9% |
| FY 2010 | $49.63M | +193.4% |
| FY 2009 | $-53.13M | — |
Source: Neurocrine Biosciences, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open NBIX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Neurocrine Biosciences, Inc. reported $748.70M of free cash flow for fiscal 2025. That was 34.4% higher than fiscal 2024. Compared with fiscal 2020, the change was +244.1%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Neurocrine Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeNeurocrine Biosciences, Inc. — frequently asked questions
What is Neurocrine Biosciences, Inc.'s free cash flow?
Neurocrine Biosciences, Inc. (NBIX) reported free cash flow of $748.70M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Neurocrine Biosciences, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.